title: Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
abstract: A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in patients with type 2 diabetes mellitus (T2DM). Medline, Embase, Cochrane Library and www. clinicaltrials. gov (up to February 15(th), 2015) were searched. Randomized controlled trials comparing dulaglutide to other drugs for T2DM were collected. Twelve RCTs were included, and the overall bias was low. As the monotherapy, compared with control (placebo, metformin and liraglutide), dulaglutide resulted in a significant reduction in HbA1c (WMD, -0.68%; 95% CI, -0.95 to -0.40), FPG (WMD, -0.90 mmol/L; 95% CI, -1.28 to -0.52), a similar risk of hypoglycemia (7.8% vs. 10.6%), less body weight loss (WMD, 0.51 kg; 95% CI, 0.27 to 0.75). As an add-on intervention with oral antihyperglycemic medication (OAM) and insulin, compared with control (placebo, sitagliptin, exenatide, liraglutide and glargine), dulaglutide lowered HbA1c (WMD, -0.51%; 95% CI, -0.68 to -0.35) and body weight significantly (WMD, -1.30 kg, 95% CI, -1.85 to -1.02) notably, and elicited a similar reduction in FPG (WMD, -0.19 mmol/L; 95% CI, -1.20 to 0.82), an similar incidence of hypoglycemia (24.5% vs. 24.5%). This meta-analysis revealed the use of dulaglutide as a monotherapy or an add-on to OAM and lispro appeared to be effective and safe for adults with T2DM.
authors.affiliation: Department of Endocrinology and metabolism, West China Hospital, Sichuan University; The third affiliated hospital of Chengdu University of Traditional Chinese Medicine.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Laboratory Medicine, West China Hospital, Sichuan University.
authors.forename: Mei
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology and metabolism, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, P.R. China.
authors.forename: Yuwei
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology and metabolism, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, P.R. China.
authors.forename: Nanwei
authors.initials: N
authors.lastname: Tong
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000077270:Exenatide; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D007328:Insulin / Q000097:blood; D000069036:Insulin Glargine / Q000008:administration & dosage / Q000009:adverse effects; D000069450:Liraglutide / Q000008:administration & dosage / Q000009:adverse effects; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects; D061214:Patient Safety; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D000068900:Sitagliptin Phosphate / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014688:Venoms / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001786:Blood Glucose; D000077270:Exenatide; D004763:Glucagon-Like Peptides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D007328:Insulin; D000069036:Insulin Glargine; D000069450:Liraglutide; D008687:Metformin; D010455:Peptides; D011993:Recombinant Fusion Proteins; D000068900:Sitagliptin Phosphate; D014688:Venoms; C517652:hemoglobin A1c protein, human; C555680:dulaglutide